期刊
NEW ENGLAND JOURNAL OF MEDICINE
卷 370, 期 12, 页码 1131-1137出版社
MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMoa1310967
关键词
-
资金
- Medical Research Council [G1001821] Funding Source: Medline
- MRC [G1001821] Funding Source: UKRI
- Medical Research Council [G1001821] Funding Source: researchfish
Hyperinsulinemic hypoglycemia is the most common cause of severe, persistent neonatal hypoglycemia. The treatment of hyperinsulinemic hypoglycemia that is unresponsive to diazoxide is subtotal pancreatectomy. We examined the effectiveness of the mammalian target of rapamycin (mTOR) inhibitor sirolimus in four infants with severe hyperinsulinemic hypoglycemia that had been unresponsive to maximal doses of diazoxide (20 mg per kilogram of body weight per day) and octreotide (35 mu g per kilogram per day). All the patients had a clear glycemic response to sirolimus, although one patient required a small dose of octreotide to maintain normoglycemia. There were no major adverse events during 1 year of follow-up.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据